Using validation cohort #1 comprised of 93 DLBCL patients treated with R-CHOP or R-CHOP–like regimens, we validated three biomarkers (TIMP-1, PGAM1, ENO1) using ELISA technology. Here, PGAM1 is linked to diffuse large B-cell lymphoma.